Glecaprevir/Pibrentasvir in patients with chronic HCV genotype 3 infection: An integrated phase 2/3 analysis

Glecaprevir coformulated with pibrentasvir (G/P) is approved to treat hepatitis C virus (HCV) infection and was highly efficacious in phase 2 and 3 studies. Treating HCV genotype (GT) 3 infection remains a priority, as these patients are harder to cure and at a greater risk for liver steatosis, fibr...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Viral Hepat
Main Authors: Flamm, Steven, Mutimer, David, Asatryan, Armen, Wang, Stanley, Rockstroh, Jürgen, Horsmans, Yves, Kwo, Paul Y., Weiland, Ola, Villa, Erica, Heo, Jeong, Gane, Edward, Ryder, Stephen D., Welzel, Tania M., Ruane, Peter J., Agarwal, Kosh, Ng, Teresa I., Xue, Zhenyi, Lovell, Sandra S., Krishnan, Preethi, Kopecky‐Bromberg, Sarah, Trinh, Roger, Mensa, Federico J., Wyles, David L.
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2018
Teme:
Original Articles
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7379735/
https://ncbi.nlm.nih.gov/pubmed/30421537
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jvh.13038
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki